In this clinical trial 50 patients with type-2 diabetes will enrolled in two groups containing 25 subjects. In group 1, patients will receive only oral hypoglycemic drugs (metformin and/or glibenclamide) and statins agents for control of blood glucose and lipids. In group 2, patients will receive the polyherbal compound in addition to those current drugs. Before treatment, the level of total cholesterol, LDL, VLDL, HDL, triglyceride, fasting blood Sugar, HbA1c, hepatic enzyme, BUN and creatinine will determined in venous blood samples of patients. Then, the polyherbal compound will administrate twice daily (dinner and lunch). The patient will keep the usual diabetic diet and the standard hypoglycemic medications during study. After 1, 2 and 3 months the patients will visited by physician to check vital signs, blood sugar and any possible side effects. After 1 and 3 months, the level of blood glucose, lipids, hepatic enzyme, BUN and creatinine will determined again. All parameters will measure using standard kits and autoanalyzer